↓ Skip to main content

Dove Medical Press

Article Metrics

Inhaled corticosteroids for chronic obstructive pulmonary disease: what is their role in therapy?

Overview of attention for article published in International Journal of Chronic Obstructive Pulmonary Disease, August 2018
Altmetric Badge

About this Attention Score

  • Above-average Attention Score compared to outputs of the same age (59th percentile)
  • Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter
5 tweeters
facebook
1 Facebook page

Citations

dimensions_citation
5 Dimensions

Readers on

mendeley
35 Mendeley
Title
Inhaled corticosteroids for chronic obstructive pulmonary disease: what is their role in therapy?
Published in
International Journal of Chronic Obstructive Pulmonary Disease, August 2018
DOI 10.2147/copd.s172240
Pubmed ID
Authors

Donald P Tashkin, Charlie Strange

Abstract

Inhaled corticosteroids (ICSs) are a mainstay of COPD treatment for patients with a history of exacerbations. Initial studies evaluating their use as monotherapy failed to show an effect on rate of pulmonary function decline in COPD, despite improvements in symptoms and reductions in exacerbations. Subsequently, ICS use in combination with long-acting β2-agonists (LABAs) was shown to provide improved reductions in exacerbations, lung function, and health status. ICS-LABA combination therapy is currently recommended for patients with a history of exacerbations despite treatment with long-acting bronchodilators alone. The presence of eosinophilic bronchial inflammation, detected by high blood eosinophil levels or a history of asthma or asthma-COPD overlap, may define a population of patients in whom ICSs may be of particular benefit. Prospective clinical studies to determine an appropriate threshold of eosinophil levels for predicting the beneficial effects of ICSs are needed. Further study is also required in COPD patients who continue to smoke to assess the impact of cell- and tissue-specific changes on ICS responsiveness. The safety profile of ICSs in COPD patients is confounded by comorbidities, age, and prior use of systemic corticosteroids. The risk of pneumonia in patients with COPD is increased, particularly with more advanced age and worse disease severity. ICS-containing therapy also has been shown to increase pneumonia risk; however, differences in study design and the definition of pneumonia events have led to substantial variability in risk estimates, and some data indicate that pneumonia risk may differ by the specific ICS used. In summary, treatment with ICSs has a role in dual and triple therapy for COPD to reduce exacerbations and improve symptoms. Careful assessment of COPD phenotypes related to risk factors, triggers, and comorbidities may assist in individualizing treatment while maximizing the benefit-to-risk ratio of ICS-containing COPD treatment.

Twitter Demographics

The data shown below were collected from the profiles of 5 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 35 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 35 100%

Demographic breakdown

Readers by professional status Count As %
Other 8 23%
Unspecified 7 20%
Professor 5 14%
Student > Doctoral Student 4 11%
Student > Bachelor 3 9%
Other 8 23%
Readers by discipline Count As %
Medicine and Dentistry 10 29%
Unspecified 9 26%
Pharmacology, Toxicology and Pharmaceutical Science 6 17%
Engineering 2 6%
Chemistry 2 6%
Other 6 17%

Attention Score in Context

This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 01 September 2018.
All research outputs
#6,838,561
of 13,454,271 outputs
Outputs from International Journal of Chronic Obstructive Pulmonary Disease
#689
of 1,637 outputs
Outputs of similar age
#107,860
of 266,909 outputs
Outputs of similar age from International Journal of Chronic Obstructive Pulmonary Disease
#23
of 45 outputs
Altmetric has tracked 13,454,271 research outputs across all sources so far. This one is in the 48th percentile – i.e., 48% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,637 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.1. This one has gotten more attention than average, scoring higher than 56% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 266,909 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 59% of its contemporaries.
We're also able to compare this research output to 45 others from the same source and published within six weeks on either side of this one. This one is in the 48th percentile – i.e., 48% of its contemporaries scored the same or lower than it.